Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Lanzolla

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Journal of the Endocrine Society|February 13, 2019
Immune Checkpoint Blockade Anti-PD-L1 as a Trigger for Autoimmune Polyendocrine SyndromeGiulia Lanzolla, Alberto Coppelli, Mirco Cosottini, et al.
JBMR Plus|May 20, 2024
Osteoblastic erythropoietin is not required for bone mass accrualGiulia Lanzolla, Christophe Merceron, Mohd Parvez Khan, et al.
Frontiers in Endocrinology|February 11, 2020
Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the TherapyGiulia Lanzolla, Guia Vannucchi, Ilaria Ionni, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|June 14, 2017
The Glu331del mutation in the CYP17A1 gene causes atypical congenital adrenal hyperplasia in a 46,XX femaleGiulia Lanzolla, Giuseppe Vancieri, Silvia Lanciotti, et al.
Pharmaceuticals (Basel, Switzerland)|September 27, 2025
Reply to Douxfils, J.; Foidart, J.-M. Critical Considerations in the Interpretation of Bone Turnover Marker Data in HormonalContraceptive Users. Comment on "Tassi et al. Hormonal Contraception and Bone Metabolism: Emerging Evidence from a Systematic Review and Meta-Analysis of Studies on Post-Pubertal and Reproductive-Age Women. <i>Pharmaceuticals</i> 2025, <i>18</i>, 61"Alice Tassi, Ambrogio P Londero, Anjeza Xholli, et al.
Pharmaceuticals (Basel, Switzerland)|January 25, 2025
Hormonal Contraception and Bone Metabolism: Emerging Evidence from a Systematic Review and Meta-Analysis of Studies on Post-Pubertal and Reproductive-Age WomenAlice Tassi, Ambrogio P Londero, Anjeza Xholli, et al.
Frontiers in Endocrinology|December 23, 2024
Ocular surface disease index in Graves' orbitopathy: a cross-sectional studyMaria Novella Maglionico, Giulia Lanzolla, Michele Figus, et al.
The Journal of Clinical Endocrinology and Metabolism|November 5, 2022
Insights Into the Role of DNA Methylation and Gene Expression in Graves OrbitopathyGiovanna Rotondo Dottore, Giulia Lanzolla, Simone Comi, et al.
Cancers|February 13, 2025
Detection of Central Compartment Lymph Node Metastasis of Thyroid Cancer: Usefulness of Intraoperative Thyroglobulin Measurement in Fine Needle Aspiration Washout with and Without Blue Dye InjectionChiara Mura, Gian Luigi Canu, Giulia Lanzolla, et al.
Journal of Endocrinological Investigation|April 12, 2021
Beneficial effect of low-dose radioiodine ablation for Graves' orbitopathy: results of a retrospective studyGiulia Lanzolla, Francesca Menconi, Francesca Nicolì, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Journal of the Endocrine Society|February 13, 2019
Immune Checkpoint Blockade Anti-PD-L1 as a Trigger for Autoimmune Polyendocrine SyndromeGiulia Lanzolla, Alberto Coppelli, Mirco Cosottini, et al.
JBMR Plus|May 20, 2024
Osteoblastic erythropoietin is not required for bone mass accrualGiulia Lanzolla, Christophe Merceron, Mohd Parvez Khan, et al.
Frontiers in Endocrinology|February 11, 2020
Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the TherapyGiulia Lanzolla, Guia Vannucchi, Ilaria Ionni, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|June 14, 2017
The Glu331del mutation in the CYP17A1 gene causes atypical congenital adrenal hyperplasia in a 46,XX femaleGiulia Lanzolla, Giuseppe Vancieri, Silvia Lanciotti, et al.
Pharmaceuticals (Basel, Switzerland)|September 27, 2025
Reply to Douxfils, J.; Foidart, J.-M. Critical Considerations in the Interpretation of Bone Turnover Marker Data in HormonalContraceptive Users. Comment on "Tassi et al. Hormonal Contraception and Bone Metabolism: Emerging Evidence from a Systematic Review and Meta-Analysis of Studies on Post-Pubertal and Reproductive-Age Women. <i>Pharmaceuticals</i> 2025, <i>18</i>, 61"Alice Tassi, Ambrogio P Londero, Anjeza Xholli, et al.
Pharmaceuticals (Basel, Switzerland)|January 25, 2025
Hormonal Contraception and Bone Metabolism: Emerging Evidence from a Systematic Review and Meta-Analysis of Studies on Post-Pubertal and Reproductive-Age WomenAlice Tassi, Ambrogio P Londero, Anjeza Xholli, et al.
Frontiers in Endocrinology|December 23, 2024
Ocular surface disease index in Graves' orbitopathy: a cross-sectional studyMaria Novella Maglionico, Giulia Lanzolla, Michele Figus, et al.
The Journal of Clinical Endocrinology and Metabolism|November 5, 2022
Insights Into the Role of DNA Methylation and Gene Expression in Graves OrbitopathyGiovanna Rotondo Dottore, Giulia Lanzolla, Simone Comi, et al.
Cancers|February 13, 2025
Detection of Central Compartment Lymph Node Metastasis of Thyroid Cancer: Usefulness of Intraoperative Thyroglobulin Measurement in Fine Needle Aspiration Washout with and Without Blue Dye InjectionChiara Mura, Gian Luigi Canu, Giulia Lanzolla, et al.
Journal of Endocrinological Investigation|April 12, 2021
Beneficial effect of low-dose radioiodine ablation for Graves' orbitopathy: results of a retrospective studyGiulia Lanzolla, Francesca Menconi, Francesca Nicolì, et al.
Pageof 4